Silverarc Capital Management
Latest statistics and disclosures from Silverarc Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, RYTM, RNA, NUVL, URGN, and represent 24.76% of Silverarc Capital Management's stock portfolio.
- Added to shares of these 10 stocks: ABVX (+$46M), United Therapeutics Corp Cmn Stk cmn (+$25M), DNTH (+$23M), RNA (+$19M), GUTS (+$17M), Ultragenyx Pharmaceutical In (+$16M), QURE (+$15M), NUVL (+$12M), COGT (+$12M), CYTK (+$12M).
- Started 37 new stock positions in BIIB, Bridgebio Oncology Therapeut, ARCT, IMVT, ZURA, MRSN, CRNX, Atyr Pharma Inc put, COGT, Biodesix.
- Reduced shares in these 10 stocks: MRUS (-$39M), VRNA (-$34M), , Merus N V (-$20M), ETNB (-$20M), SLNO (-$17M), , URGN (-$8.9M), PFE (-$8.3M), Nuvalent (-$7.6M).
- Sold out of its positions in Akero Therapeutics Inc call, BDSX, Cogent Communications Group cmn, ETNB, Hims & Hers Health, Mersana Therapeutics, MTSR, NBIX, Nuvalent, ORKA. PFE, Spdr S&p Oil & Gas Exp & Pr call, SGMT, SLNO, GPCR, TRML, VRNA, HLXB, MRUS, Merus N V.
- Silverarc Capital Management was a net buyer of stock by $101M.
- Silverarc Capital Management has $742M in assets under management (AUM), dropping by 36.75%.
- Central Index Key (CIK): 0001816307
Tip: Access up to 7 years of quarterly data
Positions held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Silverarc Capital Management
Silverarc Capital Management holds 82 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa Sponsored Ads (ABVX) | 6.2 | $46M | NEW | 540k | 84.90 |
|
| Rhythm Pharmaceuticals (RYTM) | 5.0 | $37M | -7% | 370k | 100.99 |
|
| Avidity Biosciences Ord (RNA) | 5.0 | $37M | +106% | 845k | 43.57 |
|
| Nuvalent Inc-a (NUVL) | 4.3 | $32M | +58% | 372k | 86.48 |
|
| Urogen Pharma (URGN) | 4.2 | $32M | -22% | 1.6M | 19.95 |
|
| Akero Therapeutics (AKRO) | 4.1 | $31M | -9% | 644k | 47.48 |
|
| Insmed Com Par $.01 (INSM) | 4.0 | $30M | -17% | 207k | 144.01 |
|
| Dianthus Therapeutics (DNTH) | 3.6 | $27M | +604% | 675k | 39.35 |
|
| Uniqure Nv SHS (QURE) | 3.6 | $27M | +124% | 455k | 58.37 |
|
| Cg Oncology (CGON) | 3.5 | $26M | +17% | 638k | 40.28 |
|
| United Therapeutics Corp Del Put Put Option | 3.4 | $25M | NEW | 60k | 419.21 |
|
| Oric Pharmaceuticals (ORIC) | 3.2 | $23M | +8% | 1.9M | 12.00 |
|
| Cidara Therapeutics Com New (CDTX) | 2.9 | $21M | +112% | 221k | 95.76 |
|
| Fractyl Health (GUTS) | 2.3 | $17M | +5132% | 11M | 1.59 |
|
| Kalvista Pharmaceuticals (KALV) | 2.2 | $17M | -25% | 1.4M | 12.18 |
|
| Kodiak Sciences (KOD) | 2.2 | $16M | +149% | 1.0M | 16.37 |
|
| Ultragenyx Pharmaceutical In Call Call Option | 2.1 | $16M | NEW | 528k | 30.08 |
|
| Gossamer Bio (GOSS) | 1.7 | $13M | -7% | 4.8M | 2.63 |
|
| Cogent Biosciences (COGT) | 1.6 | $12M | NEW | 815k | 14.36 |
|
| Cytokinetics Com New (CYTK) | 1.6 | $12M | NEW | 211k | 54.96 |
|
| Vaxcyte (PCVX) | 1.5 | $11M | +9% | 314k | 36.02 |
|
| Biogen Idec (BIIB) | 1.5 | $11M | NEW | 80k | 140.08 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.4 | $11M | -38% | 54k | 198.81 |
|
| Compass Therapeutics (CMPX) | 1.3 | $9.9M | +126% | 2.8M | 3.50 |
|
| Amylyx Pharmaceuticals (AMLX) | 1.3 | $9.5M | NEW | 700k | 13.59 |
|
| Verastem Com New (VSTM) | 1.2 | $9.2M | NEW | 1.0M | 8.83 |
|
| Avalo Therapeutics Com New (AVTX) | 1.2 | $9.2M | NEW | 721k | 12.71 |
|
| Olema Pharmaceuticals (OLMA) | 1.2 | $9.1M | NEW | 934k | 9.79 |
|
| Celldex Therapeutics Com New (CLDX) | 1.2 | $9.0M | +75% | 349k | 25.87 |
|
| Scholar Rock Hldg Corp (SRRK) | 1.2 | $8.7M | -31% | 234k | 37.24 |
|
| Veracyte (VCYT) | 1.1 | $8.1M | -47% | 236k | 34.33 |
|
| Syndax Pharmaceuticals (SNDX) | 1.0 | $7.1M | +15% | 464k | 15.38 |
|
| Rapport Therapeutics (RAPP) | 0.8 | $6.1M | NEW | 204k | 29.70 |
|
| Miragen Therapeutics (VRDN) | 0.8 | $5.6M | NEW | 260k | 21.58 |
|
| Alkermes SHS (ALKS) | 0.7 | $5.4M | NEW | 181k | 30.00 |
|
| Trevi Therapeutics (TRVI) | 0.7 | $5.4M | +9% | 589k | 9.15 |
|
| Bridgebio Oncology Therapeut Com New | 0.7 | $5.3M | NEW | 457k | 11.58 |
|
| Abeona Therapeutics Com New (ABEO) | 0.7 | $5.3M | +8% | 995k | 5.28 |
|
| Lexeo Therapeutics (LXEO) | 0.7 | $5.2M | NEW | 779k | 6.64 |
|
| Cogent Biosciences Call Call Option | 0.7 | $5.2M | NEW | 360k | 14.36 |
|
| Monte Rosa Therapeutics (GLUE) | 0.7 | $5.1M | NEW | 695k | 7.41 |
|
| Compugen Ord (CGEN) | 0.7 | $4.9M | +9% | 3.3M | 1.47 |
|
| Pharvaris N V (PHVS) | 0.6 | $4.6M | NEW | 184k | 24.95 |
|
| Celcuity (CELC) | 0.6 | $4.4M | NEW | 89k | 49.40 |
|
| Cerus Corporation (CERS) | 0.6 | $4.3M | +9% | 2.7M | 1.59 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.6 | $4.2M | NEW | 1.9M | 2.22 |
|
| Tela Bio (TELA) | 0.6 | $4.1M | 2.8M | 1.49 |
|
|
| Aardvark Therapeutics (AARD) | 0.6 | $4.1M | +7% | 307k | 13.29 |
|
| Bicara Therapeutics (BCAX) | 0.5 | $4.0M | NEW | 251k | 15.79 |
|
| Benitec Biopharma Com New (BNTC) | 0.5 | $3.9M | +9% | 276k | 14.03 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.5 | $3.5M | +17% | 89k | 38.83 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.5 | $3.4M | +2724% | 141k | 24.25 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.4 | $3.3M | NEW | 231k | 14.24 |
|
| Sionna Therapeutics (SION) | 0.4 | $3.2M | -41% | 109k | 29.41 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.4 | $3.1M | NEW | 721k | 4.33 |
|
| Mineralys Therapeutics (MLYS) | 0.4 | $3.0M | -30% | 80k | 37.92 |
|
| Erasca (ERAS) | 0.4 | $3.0M | -46% | 1.4M | 2.18 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.4 | $2.7M | +412% | 51k | 53.00 |
|
| Elutia Cl A Com (ELUT) | 0.3 | $2.5M | +3% | 2.9M | 0.89 |
|
| Delcath Sys Com New (DCTH) | 0.3 | $2.2M | +97% | 203k | 10.75 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.3 | $2.1M | NEW | 50k | 41.65 |
|
| Camp4 Therapeutics Corp (CAMP) | 0.3 | $2.0M | NEW | 654k | 3.00 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.3 | $2.0M | NEW | 166k | 11.75 |
|
| Dyne Therapeutics (DYN) | 0.2 | $1.3M | NEW | 100k | 12.65 |
|
| Lb Pharmaceuticals Com Shs | 0.1 | $1.1M | NEW | 70k | 15.79 |
|
| Capricor Therapeutics Put Put Option | 0.1 | $1.0M | 145k | 7.21 |
|
|
| Mersana Therapeutics (MRSN) | 0.1 | $1.0M | NEW | 134k | 7.76 |
|
| Radiopharm Theranostics Sponsored Ads (RADX) | 0.1 | $1.0M | 187k | 5.52 |
|
|
| Atyr Pharma Put Put Option | 0.1 | $901k | NEW | 1.3M | 0.72 |
|
| Immunovant (IMVT) | 0.1 | $806k | NEW | 50k | 16.12 |
|
| Arcturus Therapeutics Hldgs Put Put Option | 0.1 | $774k | NEW | 42k | 18.43 |
|
| Syndax Pharmaceuticals Call Call Option | 0.1 | $770k | 50k | 15.39 |
|
|
| Ultragenyx Pharmaceutical In Put Put Option | 0.1 | $752k | NEW | 25k | 30.08 |
|
| Moonlake Immunotherapeutics Call Call Option | 0.1 | $466k | NEW | 65k | 7.17 |
|
| Modular Med Com New (MODD) | 0.1 | $448k | -9% | 640k | 0.70 |
|
| Biodesix | 0.1 | $375k | NEW | 50k | 7.55 |
|
| Mbx Biosciences (MBX) | 0.0 | $263k | NEW | 15k | 17.50 |
|
| Enliven Therapeutics (ELVN) | 0.0 | $219k | +6% | 11k | 20.47 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.0 | $215k | -63% | 30k | 7.17 |
|
| Arcturus Therapeutics Hldg I (ARCT) | 0.0 | $64k | NEW | 3.4k | 18.43 |
|
| Nektar Therapeutics Com New (NKTR) | 0.0 | $21k | +5% | 365.00 | 56.90 |
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $4.1k | 105k | 0.04 |
|
Past Filings by Silverarc Capital Management
SEC 13F filings are viewable for Silverarc Capital Management going back to 2020
- Silverarc Capital Management 2025 Q3 filed Nov. 12, 2025
- Silverarc Capital Management 2025 Q2 filed Aug. 14, 2025
- Silverarc Capital Management 2025 Q1 filed May 14, 2025
- Silverarc Capital Management 2024 Q4 filed Feb. 14, 2025
- Silverarc Capital Management 2024 Q3 filed Nov. 14, 2024
- Silverarc Capital Management 2024 Q2 filed Aug. 14, 2024
- Silverarc Capital Management 2024 Q1 filed May 15, 2024
- Silverarc Capital Management 2023 Q4 filed Feb. 14, 2024
- Silverarc Capital Management 2023 Q3 filed Nov. 13, 2023
- Silverarc Capital Management 2023 Q2 filed Aug. 14, 2023
- Silverarc Capital Management 2023 Q1 filed May 15, 2023
- Silverarc Capital Management 2022 Q4 filed Feb. 14, 2023
- Silverarc Capital Management 2022 Q3 filed Oct. 28, 2022
- Silverarc Capital Management 2022 Q2 filed July 25, 2022
- Silverarc Capital Management 2022 Q1 filed May 13, 2022
- Silverarc Capital Management 2021 Q4 filed Feb. 14, 2022